AR108257A1 - Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas - Google Patents

Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas

Info

Publication number
AR108257A1
AR108257A1 ARP170101104A ARP170101104A AR108257A1 AR 108257 A1 AR108257 A1 AR 108257A1 AR P170101104 A ARP170101104 A AR P170101104A AR P170101104 A ARP170101104 A AR P170101104A AR 108257 A1 AR108257 A1 AR 108257A1
Authority
AR
Argentina
Prior art keywords
acrylamide
hydroxy
dietilamino
bencimidazol
butil
Prior art date
Application number
ARP170101104A
Other languages
English (en)
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of AR108257A1 publication Critical patent/AR108257A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

Reivindicación 1: Un polimorfo cristalino de diclorhidrato de 3-[2-butil-1-(2-dietilamino-etil)-1H-benzimidazol-5-il]-N-hidroxi-acrilamida 2,5 hidrato caracterizado porque tiene un patrón de difracción de rayos X en polvo con picos a 6,46, 20,26, y 26,68 º2q ± 0,1º 2q.
ARP170101104A 2016-05-02 2017-04-28 Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas AR108257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02

Publications (1)

Publication Number Publication Date
AR108257A1 true AR108257A1 (es) 2018-08-01

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101104A AR108257A1 (es) 2016-05-02 2017-04-28 Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas

Country Status (20)

Country Link
US (2) US10626092B2 (es)
EP (2) EP3452035B1 (es)
JP (1) JP2019514905A (es)
KR (1) KR20190005904A (es)
CN (1) CN109414425A (es)
AR (1) AR108257A1 (es)
AU (1) AU2017261218A1 (es)
BR (1) BR112018072439A2 (es)
CA (1) CA3022011A1 (es)
CL (1) CL2018003109A1 (es)
CO (1) CO2018012941A2 (es)
EA (1) EA201892341A1 (es)
ES (1) ES2886495T3 (es)
IL (1) IL262578A (es)
MA (1) MA44880A (es)
MX (1) MX2018013349A (es)
PH (1) PH12018502296B1 (es)
SG (1) SG11201809471UA (es)
TW (1) TW201741286A (es)
WO (1) WO2017192451A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157742A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
US20230159468A1 (en) 2020-04-22 2023-05-25 Macfarlan Smith Limited Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
ATE198601T1 (de) 1992-05-20 2001-01-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
EP1144385B1 (en) 1999-01-13 2005-08-17 Warner-Lambert Company Llc Benzoheterocycles and their use as mek inhibitors
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
JP2003503351A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Srcキナーゼ阻害化合物
CA2378381A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
AU783504C (en) 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
RU2223761C2 (ru) 1999-12-27 2004-02-20 Джапан Тобакко Инк. Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
WO2008108741A1 (en) * 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
AU2003215112A1 (en) 2002-02-07 2003-09-02 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
MXPA04008894A (es) 2002-03-13 2005-06-20 Array Biopharma Inc Derivados de bencimidazol n3 alquilados como inhibidores de mek.
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
KR20040101520A (ko) 2002-04-16 2004-12-02 데이진 가부시키가이샤 Ccr3 길항작용을 갖는 피페리딘 유도체
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
BRPI0414581C1 (pt) 2003-09-22 2021-05-25 Mei Pharma Inc composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
EP1937650B1 (en) 2005-09-08 2011-06-15 S*BIO Pte Ltd Heterocyclic compounds
AU2006201177B2 (en) * 2005-09-08 2012-06-14 Mei Pharma, Inc. Heterocyclic compounds
SI2914254T1 (sl) * 2012-10-30 2020-07-31 Mei Pharma, Inc. Kombinacija terapij za zdravljenje kemorezistentnih rakov

Also Published As

Publication number Publication date
PH12018502296A1 (en) 2019-07-08
BR112018072439A2 (pt) 2019-02-19
US20200317621A1 (en) 2020-10-08
CN109414425A (zh) 2019-03-01
CL2018003109A1 (es) 2019-04-26
SG11201809471UA (en) 2018-11-29
EP3452035B1 (en) 2021-07-07
ES2886495T3 (es) 2021-12-20
US20190152923A1 (en) 2019-05-23
KR20190005904A (ko) 2019-01-16
EP3939966A1 (en) 2022-01-19
WO2017192451A1 (en) 2017-11-09
TW201741286A (zh) 2017-12-01
MX2018013349A (es) 2019-02-20
IL262578A (en) 2018-12-31
CO2018012941A2 (es) 2018-12-28
EP3452035A4 (en) 2019-09-25
JP2019514905A (ja) 2019-06-06
MA44880A (fr) 2021-03-17
PH12018502296B1 (en) 2019-07-08
AU2017261218A1 (en) 2018-11-29
US10626092B2 (en) 2020-04-21
EP3452035A1 (en) 2019-03-13
CA3022011A1 (en) 2017-11-09
EA201892341A1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
IL280747B (en) Modified pyrrolizine compounds and their uses
EP3449521A4 (en) POLYCRYSTALLINE LAMINATED METAL OXIDES COMPRISING NANOCRYSTALS
HK1258689A1 (zh) 氨基噻唑化合物及其用途
HK1254654A1 (zh) 4,6-亞嘧啶基衍生物及其用途
IL278122B1 (en) Petridinon compounds and their uses
GB201507110D0 (en) Sintered polycrystalline body
IL272055A (en) 8,1-naphthyridinone compounds and their uses
AR108257A1 (es) Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
GB201616439D0 (en) Compounds and uses
SG11201801534RA (en) 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof
HUE048810T2 (hu) Eljárás gipszkarton lapok elõállítására
ZA202103846B (en) Autografting tool for deep reach applications
IL279483A (en) Cyanotriazole compounds and their uses
IL277502A (en) Compounds and uses for them
GB2552312B (en) Ceramic objects and methods for manufacturing the same
HK1258687A1 (zh) 噻唑烷酮化合物及其用途
SI3795576T1 (sl) 1,3-maščobne spojine diola in njihovi glikozilirani derivati
GB2562467B (en) Chemical Milling
SG11201705533SA (en) Levelling compound, its use and manufacture
GB201801102D0 (en) New compounds and uses
HUE055512T2 (hu) Nagy denzitású vizes kútfolyadékok
PL3105243T3 (pl) Pochodne 2',3'-dideoksy-5-fluorourydyny, sposób ich wytwarzania i zastosowanie
GB201806349D0 (en) New compounds and uses
MacKay The engine of memory
HUE061661T2 (hu) Elektródaegység és eljárás annak elõállítására

Legal Events

Date Code Title Description
FB Suspension of granting procedure